NCT04256759View on ClinicalTrials.gov

Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

December 1, 2024

Study Completion Date

July 31, 2025

Conditions

Pruritus

Interventions

DRUG

Dupilumab 300Mg Solution for Injection

Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.

Trial Locations (1)

32224

Mayo Clinic Florida, Jacksonville

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Mayo Clinic

OTHER

NCT04256759 - Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus | Biotech Hunter | Biotech Hunter